Hjem › Metastatisk kreft › New Mexico
Kliniske studier for Metastatisk kreft i New Mexico
13 studier for Metastatisk kreft søker deltakere på steder i New Mexico.
Byer i New Mexico
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of New Mexico Cancer Center, Albuquerque
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564377Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07222800A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06103864Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
- CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07222566Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- New Mexico Oncology Hematology Consultants, Albuquerque
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07028489A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Optimum Clinical Research Group, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of New Mexico Comprehensive Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 29. jul. 2026 · NCT07044336A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Christus St Vincent Regional Medical Center, Santa Fe
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT06657144A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- New Mexico Oncology Hematology Consultants Ltd, Albuquerque
RekruttererFase 1
Alder 18 og eldre · Menn · Oppdatert 4. feb. 2026 · NCT04729114VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Presbyterian Kaseman Hospital (site 208), Albuquerque
RekruttererFase 1/2
Alder 18 til 80 · Alle kjønn · Oppdatert 11. des. 2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.